- Home
- VYNE vs CVKD Comparison
VYNE vs CVKD Comparison
Compare VYNE & CVKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VYNE | CVKD |
|---|---|---|
| Founded | 2003 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5M | 20.7M |
| IPO Year | 2018 | 2023 |
Fundamental Metrics
Financial Performance| Metric | VYNE | CVKD |
|---|---|---|
| Price | $0.38 | $11.06 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 1 | 1 |
| Target Price | N/A | ★ $32.00 |
| AVG Volume (30 Days) | ★ 900.5K | 41.0K |
| Earning Date | 11-06-2025 | 11-10-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $524,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $16.67 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 6.29 | N/A |
| 52 Week Low | $0.28 | $8.12 |
| 52 Week High | $4.30 | $22.90 |
Technical Indicators
Market Signals| Indicator | VYNE | CVKD |
|---|---|---|
| Relative Strength Index (RSI) | 50.67 | 51.02 |
| Support Level | $0.36 | $9.55 |
| Resistance Level | $0.42 | $12.00 |
| Average True Range (ATR) | 0.03 | 0.91 |
| MACD | 0.00 | 0.25 |
| Stochastic Oscillator | 41.63 | 74.23 |
Price Performance
Historical ComparisonAbout VYNE VYNE Therapeutics Inc.
VYNE Therapeutics Inc is a biopharmaceutical company focused on developing proprietary, innovative and differentiated therapies for the treatment of immuno-inflammatory conditions. Its advanced product candidate is FMX114, which is being evaluated for the potential treatment of mild-to-moderate AD (atopic dermatitis). The company is also in the pre-clinical stages of developing products containing BET (Bromodomain and Extra-Terminal Domain) inhibitor compounds. Its products include AMZEEQ, ZILXI, and FCD105.
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.